Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 5/2008

01.11.2008 | Original Article

Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial

verfasst von: Aybike Tazegül, Hüseyin Görkemli, Suna Özdemir, T. Murad Aktan

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the efficacy of gonadotropin releasing hormone antagonist (GnRH) in poor responders undergoing in vitro fertilization.

Study design

Ninety-six patients with poor ovarian response in previous treatment cycles were prospectively randomized into two groups. Forty-four patients were stimulated with GnRH antagonist multidose protocol and 45 patients received a standard long agonist protocol. Ovarian response was evaluated by transvaginal ultrasound and hormonal parameters. Cycle characteristics and treatment outcomes were statistically compared between groups.

Results

There was significantly reduced duration of stimulation and consumption of gonadotrophins in the antagonist group when compared to the agonist group. The estradiol concentrations on the day of human chorionic gonadotropin (hCG) injection, the number of oocytes retrieved, and the number of embryos transferred were similar for both groups. In the antagonist group, eight (18.1%) ongoing pregnancies were achieved and in the agonist group, ten (22.2%) clinical pregnancies were achieved but the difference was not statistically significant.

Conclusion

The present study was not powered to detect clinically relevant differences between two protocols in outcomes such as pregnancy rate, with confidence.
Literatur
1.
Zurück zum Zitat Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J (2003) Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 9:61–76PubMedCrossRef Tarlatzis BC, Zepiridis L, Grimbizis G, Bontis J (2003) Clinical management of low ovarian response to stimulation for IVF: a systematic review. Hum Reprod Update 9:61–76PubMedCrossRef
2.
Zurück zum Zitat Hofmann GE, Toner JP Muasher SJ, Jones GS (1989) High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization. J In Vitro Fert Embryo Transf 6:285–289PubMedCrossRef Hofmann GE, Toner JP Muasher SJ, Jones GS (1989) High-dose follicle-stimulating hormone (FSH) ovarian stimulation in low-responder patients for in vitro fertilization. J In Vitro Fert Embryo Transf 6:285–289PubMedCrossRef
3.
Zurück zum Zitat De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M (2000) Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod 15:17–20PubMedCrossRef De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M (2000) Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod 15:17–20PubMedCrossRef
4.
Zurück zum Zitat Karacan M, Erkan H, Karabulut O, Sarıkamış B, Çamlıbel T, Benhabib M (2001) Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a. J Reprod Med 46:485–489PubMed Karacan M, Erkan H, Karabulut O, Sarıkamış B, Çamlıbel T, Benhabib M (2001) Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a. J Reprod Med 46:485–489PubMed
6.
Zurück zum Zitat Olivennes F, Alvarez S, Bouchard P, Franchin R, Salat-Baroux J, Frydman R (1998) The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 13:2411–2414PubMedCrossRef Olivennes F, Alvarez S, Bouchard P, Franchin R, Salat-Baroux J, Frydman R (1998) The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Hum Reprod 13:2411–2414PubMedCrossRef
7.
Zurück zum Zitat Fasouliotis SJ, Simon A, Laufer N (2000) Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet. J Assist Reprod Genet 17:357–373PubMedCrossRef Fasouliotis SJ, Simon A, Laufer N (2000) Evaluation and treatment of low responders in assisted reproductive technology: a challenge to meet. J Assist Reprod Genet 17:357–373PubMedCrossRef
8.
Zurück zum Zitat Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM (2006) GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13:628–638PubMedCrossRef Griesinger G, Diedrich K, Tarlatzis BC, Kolibianakis EM (2006) GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 13:628–638PubMedCrossRef
9.
Zurück zum Zitat Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M (2005) GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod Biomed Online 11:189–193PubMed Marci R, Caserta D, Dolo V, Tatone C, Pavan A, Moscarini M (2005) GnRH antagonist in IVF poor-responder patients: results of a randomized trial. Reprod Biomed Online 11:189–193PubMed
10.
Zurück zum Zitat Germond M, Senn A, Reymond O et al (1990) Why lose an in vitro fertilization cycle when stimulation fails? Fertil Steril 53:936–938PubMed Germond M, Senn A, Reymond O et al (1990) Why lose an in vitro fertilization cycle when stimulation fails? Fertil Steril 53:936–938PubMed
11.
Zurück zum Zitat Cheung LP et al (2005) GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 20:616–621PubMedCrossRef Cheung LP et al (2005) GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 20:616–621PubMedCrossRef
12.
Zurück zum Zitat Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S, Lewin A, Hurwitz A, Simon A (2003) Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. J Assist Reprod Genet 20:455–460PubMedCrossRef Fasouliotis SJ, Laufer N, Sabbagh-Ehrlich S, Lewin A, Hurwitz A, Simon A (2003) Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF. J Assist Reprod Genet 20:455–460PubMedCrossRef
13.
Zurück zum Zitat Nikolettos N, Al-Hasani S, Felberbaum R et al (2001) Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 97:202–207PubMedCrossRef Nikolettos N, Al-Hasani S, Felberbaum R et al (2001) Gonadotropin-releasing hormone antagonist protocol: a novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 97:202–207PubMedCrossRef
14.
Zurück zum Zitat Copperman AB (2003) Antagonists in poor-responder patients. Fertil Steril 80:16–24CrossRef Copperman AB (2003) Antagonists in poor-responder patients. Fertil Steril 80:16–24CrossRef
15.
Zurück zum Zitat Cedrin-Durnerin I, Grange-Dujardin D, Laffy A et al (2004) Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 19:1979–1984PubMedCrossRef Cedrin-Durnerin I, Grange-Dujardin D, Laffy A et al (2004) Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 19:1979–1984PubMedCrossRef
16.
Zurück zum Zitat Kolibianakis EM, Zikopoulos K, Schiettecatte J et al (2004) Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 19:2490–2496PubMedCrossRef Kolibianakis EM, Zikopoulos K, Schiettecatte J et al (2004) Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 19:2490–2496PubMedCrossRef
17.
Zurück zum Zitat Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG (2005) Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 20:2421–2425PubMedCrossRef Ragni G, Vegetti W, Riccaboni A, Engl B, Brigante C, Crosignani PG (2005) Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome. Hum Reprod 20:2421–2425PubMedCrossRef
18.
Zurück zum Zitat Ben-Rafael Z, Lipitz S, Bider D, Mashiach S (1991) Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 55:272–275PubMed Ben-Rafael Z, Lipitz S, Bider D, Mashiach S (1991) Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levels. Fertil Steril 55:272–275PubMed
19.
Zurück zum Zitat Sheehan KL, Casper RF, Yen SS (1982) Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control. Science 215:170–172PubMedCrossRef Sheehan KL, Casper RF, Yen SS (1982) Luteal phase defects induced by an agonist of luteinizing hormone-releasing factor: a model for fertility control. Science 215:170–172PubMedCrossRef
20.
Zurück zum Zitat Diedrich K, Diedrich C, Santos E et al (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 9:788–791PubMed Diedrich K, Diedrich C, Santos E et al (1994) Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 9:788–791PubMed
21.
Zurück zum Zitat Xavier P, Gamboa C, Calejo L et al (2005) A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 120:185–189PubMedCrossRef Xavier P, Gamboa C, Calejo L et al (2005) A randomised study of GnRH antagonist (cetrorelix) versus agonist (busereline) for controlled ovarian stimulation: effect on safety and efficacy. Eur J Obstet Gynecol Reprod Biol 120:185–189PubMedCrossRef
Metadaten
Titel
Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial
verfasst von
Aybike Tazegül
Hüseyin Görkemli
Suna Özdemir
T. Murad Aktan
Publikationsdatum
01.11.2008
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 5/2008
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-008-0620-9

Weitere Artikel der Ausgabe 5/2008

Archives of Gynecology and Obstetrics 5/2008 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Welche Übungen helfen gegen Diastase recti abdominis?

30.04.2024 Schwangerenvorsorge Nachrichten

Die Autorinnen und Autoren einer aktuellen Studie aus Griechenland sind sich einig, dass Bewegungstherapie, einschließlich Übungen zur Stärkung der Bauchmuskulatur und zur Stabilisierung des Rumpfes, eine Diastase recti abdominis postpartum wirksam reduzieren kann. Doch vieles ist noch nicht eindeutig belegt.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.